These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 27401744

  • 1. Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description.
    Meacci F, Manfredi M, Infantino M, Grossi V, Benucci M.
    Ann Rheum Dis; 2016 Oct; 75(10):e62. PubMed ID: 27401744
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
    Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, Mikazane H, Lee YA, Smiyan S, Lim MJ, Kadinov V, Abud-Mendoza C, Kim H, Lee SJ, Bae Y, Kim S, Braun J.
    Ann Rheum Dis; 2017 Feb; 76(2):346-354. PubMed ID: 27117698
    [Abstract] [Full Text] [Related]

  • 3. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J.
    Arthritis Res Ther; 2016 Jan 20; 18():25. PubMed ID: 26795209
    [Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH.
    J Comp Eff Res; 2017 Nov 20; 6(8):693-712. PubMed ID: 29172717
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A, Silva-Dinis J, Saavedra MJ, Iria I, Gonçalves J, Lopes JP, Fonseca JE.
    Acta Reumatol Port; 2019 Nov 20; 44(4):303-311. PubMed ID: 31754088
    [Abstract] [Full Text] [Related]

  • 6. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
    Yoo DH, Oh C, Hong S, Park W.
    Expert Rev Clin Immunol; 2015 Nov 20; 11 Suppl 1():S15-24. PubMed ID: 26395833
    [Abstract] [Full Text] [Related]

  • 7. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
    Kim TH, Lee SS, Park W, Song YW, Suh CH, Kim S, Lee YN, Yoo DH.
    Clin Drug Investig; 2020 Jun 20; 40(6):541-553. PubMed ID: 32328979
    [Abstract] [Full Text] [Related]

  • 8. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015 Jun 20; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W.
    Ann Rheum Dis; 2017 Feb 20; 76(2):355-363. PubMed ID: 27130908
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.
    Reinisch W, Jahnsen J, Schreiber S, Danese S, Panés J, Balsa A, Park W, Kim J, Lee JU, Yoo DH.
    BioDrugs; 2017 Jun 20; 31(3):223-237. PubMed ID: 28497221
    [Abstract] [Full Text] [Related]

  • 11. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, den Broeder AA.
    Arthritis Rheumatol; 2018 Jan 20; 70(1):60-68. PubMed ID: 29045077
    [Abstract] [Full Text] [Related]

  • 12. CT-P13: design, development, and place in therapy.
    Gabbani T, Deiana S, Annese V.
    Drug Des Devel Ther; 2017 Jan 20; 11():1653-1661. PubMed ID: 28652703
    [Abstract] [Full Text] [Related]

  • 13. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U, Hong S, Oh C, Taylor P.
    Expert Rev Clin Immunol; 2015 Jan 20; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [Abstract] [Full Text] [Related]

  • 14. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
    Blair HA, Deeks ED.
    BioDrugs; 2016 Oct 20; 30(5):469-480. PubMed ID: 27650650
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.
    Germain V, Scherlinger M, Barnetche T, Schaeverbeke T, Fédération Hospitalo-universitaire ACRONIM.
    Ann Rheum Dis; 2020 Jan 20; 79(1):e11. PubMed ID: 30352888
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, Kim SH, Jung NH, Park JE, Lee YJ, Jeon DB, Lee YM, Kim JM, Park SH.
    Adv Ther; 2021 Aug 20; 38(8):4366-4387. PubMed ID: 34250583
    [Abstract] [Full Text] [Related]

  • 17. Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.
    Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, Mehsen-Cetre N, Richez C, Schaeverbeke T, FHU ACRONIM.
    Joint Bone Spine; 2018 Oct 20; 85(5):561-567. PubMed ID: 29154920
    [Abstract] [Full Text] [Related]

  • 18. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.
    Expert Rev Gastroenterol Hepatol; 2015 Oct 20; 9 Suppl 1():27-34. PubMed ID: 26395532
    [Abstract] [Full Text] [Related]

  • 19. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA.
    Eur J Clin Pharmacol; 2018 May 20; 74(5):655-661. PubMed ID: 29368188
    [Abstract] [Full Text] [Related]

  • 20. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K, Molnár T.
    Immunotherapy; 2018 Feb 20; 10(2):107-117. PubMed ID: 29124994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.